Diamonds and Dogs


Sarepta Therapeutics  (SRPT) keeps shooting higher. Drugmaker, Sarepta is up 3% after HMO provider Cigna will now cover their Duchenne muscular dystrophy drug, eteplirsen for their clients. Sarepta also received an upgrade at RBC Capital with a $108 price target based on some pretty conservative assumptions, which represent potential for real upside for the drug. Sarepta's stock is up 100% in the last two weeks and now the RBC analyst thinks the stock could jump another 77%. Not bad.

Shareholders are cashing in their Paychex (PAYX).  The Rochester, NY-based payroll firm beat earnings of 60 cents per share, surpassing consensus estimates of 57 cents per share. Revenue rose 9% year-over-year to $785.5 million, above Wall Street's projected $782.8 million in revenue. But the stock is down 4% after lowering payroll service revenue guidance to a range of 3% to 4% while also lowering net income guidance to an increase of 7%. The company reaffirmed HRS revenue to a range of 12% to 14%, but with the stock trading for 24 times earnings, the stock seems a little expensive. Good news is the stock has a great dividend yield of 3%.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.